Published in Biol Psychiatry on April 06, 2013
Social cognition in schizophrenia. Nat Rev Neurosci (2015) 1.15
Multimodal white matter imaging to investigate reduced fractional anisotropy and its age-related decline in schizophrenia. Psychiatry Res (2014) 0.93
The Placenta as a Mediator of Stress Effects on Neurodevelopmental Reprogramming. Neuropsychopharmacology (2015) 0.89
Accelerated white matter aging in schizophrenia: role of white matter blood perfusion. Neurobiol Aging (2014) 0.88
Does diffusion MRI tell us anything about the white matter? An overview of methods and pitfalls. Schizophr Res (2014) 0.86
In vivo imaging of neuroinflammation in schizophrenia. Schizophr Res (2015) 0.86
The Paradoxical Relationship between White Matter, Psychopathology and Cognition in Schizophrenia: A Diffusion Tensor and Proton Spectroscopic Imaging Study. Neuropsychopharmacology (2015) 0.81
Consequences at adulthood of transient inactivation of the parahippocampal and prefrontal regions during early development: new insights from a disconnection animal model for schizophrenia. Front Behav Neurosci (2014) 0.79
Alterations in frontal white matter neurochemistry and microstructure in schizophrenia: implications for neuroinflammation. Transl Psychiatry (2015) 0.79
Glial and axonal changes in systemic lupus erythematosus measured with diffusion of intracellular metabolites. Brain (2016) 0.78
Myelin vs axon abnormalities in white matter in bipolar disorder. Neuropsychopharmacology (2015) 0.77
Diving deep into white matter to improve our understanding of the pathophysiology of schizophrenia. Biol Psychiatry (2013) 0.77
Reproducibility and optimization of in vivo human diffusion-weighted MRS of the corpus callosum at 3 T and 7 T. NMR Biomed (2015) 0.77
Preliminary Observations on Sensitivity and Specificity of Magnetization Transfer Asymmetry for Imaging Myelin of Rat Brain at High Field. Biomed Res Int (2015) 0.77
Glutathione Deficit Affects the Integrity and Function of the Fimbria/Fornix and Anterior Commissure in Mice: Relevance for Schizophrenia. Int J Neuropsychopharmacol (2015) 0.76
Comparing free water imaging and magnetization transfer measurements in schizophrenia. Schizophr Res (2014) 0.76
Quetiapine Ameliorates Schizophrenia-Like Behaviors and Protects Myelin Integrity in Cuprizone Intoxicated Mice: The Involvement of Notch Signaling Pathway. Int J Neuropsychopharmacol (2015) 0.76
Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia. Nutrients (2015) 0.76
Psychiatric disorders biochemical pathways unraveled by human brain proteomics. Eur Arch Psychiatry Clin Neurosci (2016) 0.75
Dietary supplementation with n-3 fatty acids from weaning limits brain biochemistry and behavioural changes elicited by prenatal exposure to maternal inflammation in the mouse model. Transl Psychiatry (2015) 0.75
Impaired neurodevelopment by the low complexity domain of CPEB4 reveals a convergent pathway with neurodegeneration. Sci Rep (2016) 0.75
Genome-wide discovered psychosis-risk gene ZNF804A impacts on white matter microstructure in health, schizophrenia and bipolar disorder. PeerJ (2016) 0.75
ST8SIA2 promotes oligodendrocyte differentiation and the integrity of myelin and axons. Glia (2016) 0.75
White matter abnormalities of microstructure and physiological noise in schizophrenia. Brain Imaging Behav (2015) 0.75
Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry (2017) 0.75
Fornix Structural Connectivity and Allostatic Load: Empirical Evidence from Schizophrenia Patients and Healthy Controls. Psychosom Med (2017) 0.75
Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed (2000) 8.18
Aberrant "default mode" functional connectivity in schizophrenia. Am J Psychiatry (2007) 7.08
Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci (2008) 6.97
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A (2009) 6.09
Diffusion tensor imaging of the brain. Neurotherapeutics (2007) 5.37
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet (2003) 4.84
A review of diffusion tensor imaging studies in schizophrenia. J Psychiatr Res (2005) 4.34
In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med (1999) 4.26
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull (2009) 3.82
DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage (2005) 2.84
Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study. Biol Psychiatry (2003) 2.78
Myelination and the trophic support of long axons. Nat Rev Neurosci (2010) 2.47
Insights into brain microstructure from the T2 distribution. Magn Reson Imaging (2006) 2.18
Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients. Am J Psychiatry (2008) 2.11
Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI). Magn Reson Med (2009) 1.99
Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J Neurosci (2008) 1.96
Diffusion tensor imaging of the superior longitudinal fasciculus and working memory in recent-onset schizophrenia. Biol Psychiatry (2007) 1.89
Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry (2003) 1.79
Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem (2001) 1.77
A diffusion tensor imaging study of fasciculi in schizophrenia. Am J Psychiatry (2007) 1.71
Are anticorrelated networks in the brain relevant to schizophrenia? Schizophr Bull (2007) 1.65
Diffusion tensor imaging in psychiatric disorders. Top Magn Reson Imaging (2008) 1.60
Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed (1997) 1.60
Magnetic resonance imaging of myelin. Neurotherapeutics (2007) 1.58
What is the optimal value of the g-ratio for myelinated fibers in the rat CNS? A theoretical approach. PLoS One (2009) 1.55
Proton echo-planar spectroscopic imaging of J-coupled resonances in human brain at 3 and 4 Tesla. Magn Reson Med (2007) 1.53
N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol (1995) 1.47
Neuropsychological correlates of diffusion tensor imaging in schizophrenia. Neuropsychology (2004) 1.43
Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol (2004) 1.32
White matter abnormalities and brain activation in schizophrenia: a combined DTI and fMRI study. Schizophr Res (2006) 1.30
Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry (1998) 1.26
The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharmacol (2007) 1.24
Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother (2009) 1.24
White matter abnormalities in bipolar disorder: insights from diffusion tensor imaging studies. J Neural Transm (Vienna) (2010) 1.22
Schizophrenia, myelination, and delayed corollary discharges: a hypothesis. Schizophr Bull (2010) 1.21
Tract-based analysis of magnetization transfer ratio and diffusion tensor imaging of the frontal and frontotemporal connections in schizophrenia. Schizophr Bull (2008) 1.21
Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res (2007) 1.19
B1-insensitive, single-shot localization and water suppression. J Magn Reson B (1996) 1.19
Application of MRS to mouse models of neurodegenerative illness. NMR Biomed (2007) 1.18
Prefrontal-thalamic-cerebellar gray matter networks and executive functioning in schizophrenia. Schizophr Res (2007) 1.17
Neuropsychological disturbance in schizophrenia: a diffusion tensor imaging study. Neuropsychology (2008) 1.17
T2 relaxation time abnormalities in bipolar disorder and schizophrenia. Magn Reson Med (2010) 1.13
The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis (1997) 1.13
Could Sex Differences in White Matter be Explained by g ratio? Front Neuroanat (2009) 1.05
The use of MR-detectable reporter molecules and ions to evaluate diffusion in normal and ischemic brain. NMR Biomed (2010) 1.03
Reduced fronto-temporal connectivity is associated with frontal gray matter density reduction and neuropsychological deficit in schizophrenia. Schizophr Res (2008) 1.03
Frontal white matter integrity as an endophenotype for schizophrenia: diffusion tensor imaging in monozygotic twins and patients' nonpsychotic relatives. Front Hum Neurosci (2009) 1.03
Isoflurane strongly affects the diffusion of intracellular metabolites, as shown by 1H nuclear magnetic resonance spectroscopy of the monkey brain. J Cereb Blood Flow Metab (2006) 0.97
Diffusion tensor spectroscopy and imaging of the arcuate fasciculus. Neuroimage (2007) 0.96
Structural disruption of the dorsal cingulum bundle is associated with impaired Stroop performance in patients with schizophrenia. Schizophr Res (2009) 0.96
Differences in apparent diffusion coefficients of brain metabolites between grey and white matter in the human brain measured at 7 T. Magn Reson Med (2011) 0.95
White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: a diffusion tensor imaging study. Psychiatry Res (2009) 0.93
Water and metabolite transverse T2 relaxation time abnormalities in the white matter in schizophrenia. Schizophr Res (2012) 0.91
Brain pathology in first-episode psychosis: magnetization transfer imaging provides additional information to MRI measurements of volume loss. Neuroimage (2009) 0.90
Diffusion-weighted in vivo localized proton MR spectroscopy of human cerebral ischemia and tumor. NMR Biomed (2002) 0.90
Temporal changes of the apparent diffusion coefficients of water and metabolites in rats with hemispheric infarction: experimental study of transhemispheric diaschisis in the contralateral hemisphere at 7 tesla. J Cereb Blood Flow Metab (2000) 0.86
Changes in apparent diffusion coefficients of metabolites in rat brain after middle cerebral artery occlusion measured by proton magnetic resonance spectroscopy. Magn Reson Med (2001) 0.84
The appearance of ADCs in the non-affected areas of the patients with MELAS. Neuroradiology (2010) 0.77
Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry (2008) 3.28
Anticorrelations in resting state networks without global signal regression. Neuroimage (2011) 3.07
Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry (2004) 3.02
Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther (2005) 2.66
Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J Psychiatry (2005) 2.18
Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry (2002) 1.86
Default mode network abnormalities in bipolar disorder and schizophrenia. Psychiatry Res (2010) 1.84
Abnormal medial prefrontal cortex resting-state connectivity in bipolar disorder and schizophrenia. Neuropsychopharmacology (2011) 1.68
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). Bioorg Med Chem Lett (2005) 1.60
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry (2008) 1.58
CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology (Berl) (2011) 1.57
Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett (2006) 1.55
Reduced sleep spindles and spindle coherence in schizophrenia: mechanisms of impaired memory consolidation? Biol Psychiatry (2011) 1.52
Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther (2009) 1.42
Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol Psychiatry (2010) 1.38
Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology (2009) 1.36
The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry (2008) 1.31
Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed (2009) 1.26
A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A (2006) 1.23
Behavioral and anatomical interactions between dopamine and corticotropin-releasing factor in the rat. J Neurosci (2006) 1.22
Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry (2005) 1.20
Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol (2011) 1.20
Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol (2010) 1.19
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem (2007) 1.15
8-epi-Salvinorin B: crystal structure and affinity at the kappa opioid receptor. Beilstein J Org Chem (2007) 1.14
T2 relaxation time abnormalities in bipolar disorder and schizophrenia. Magn Reson Med (2010) 1.13
Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res (2009) 1.11
Delirious mania: clinical features and treatment response. J Affect Disord (2008) 1.11
Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. Am J Med Genet (2002) 1.11
Low-field magnetic stimulation in bipolar depression using an MRI-based stimulator. Am J Psychiatry (2004) 1.10
Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry (2011) 1.10
Cortical gray matter differences identified by structural magnetic resonance imaging in pediatric bipolar disorder. Bipolar Disord (2005) 1.07
Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology (2008) 1.07
Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res (2003) 1.04
Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry (2012) 1.04
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg Med Chem Lett (2011) 1.03
Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence. Neuropharmacology (2009) 1.00
Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology (2010) 1.00
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl) (2010) 1.00
Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor. Bioorg Med Chem (2008) 0.99
Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry (2004) 0.98
Catatonia in psychotic patients: clinical features and treatment response. J Neuropsychiatry Clin Neurosci (2011) 0.98
N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy. J Pharmacol Exp Ther (2007) 0.98
Activation of raphe efferents to the medial prefrontal cortex by corticotropin-releasing factor: correlation with anxiety-like behavior. Biol Psychiatry (2007) 0.97
Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology (2012) 0.97
Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity. Neuropsychopharmacology (2013) 0.97
Role of the bed nucleus of the stria terminalis (BST) in the expression of conditioned fear. Ann N Y Acad Sci (2006) 0.96
31Phosphorus magnetic resonance spectroscopy study of tissue specific changes in high energy phosphates before and after sertraline treatment of geriatric depression. Int J Geriatr Psychiatry (2009) 0.95
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol (2012) 0.95
Clinical characteristics influencing age at onset in psychotic disorders. Compr Psychiatry (2008) 0.95
Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol (2004) 0.95
Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic. Neuropsychopharmacology (2012) 0.93
Functional connectivity of left Heschl's gyrus in vulnerability to auditory hallucinations in schizophrenia. Schizophr Res (2012) 0.93
Relationship between genetic variation in the glutaminase gene GLS1 and brain glutamine/glutamate ratio measured in vivo. Biol Psychiatry (2011) 0.91
A genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug target. PLoS Genet (2013) 0.91
The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized placebo-controlled trial. Sleep (2013) 0.91
Water and metabolite transverse T2 relaxation time abnormalities in the white matter in schizophrenia. Schizophr Res (2012) 0.91
Brain metabolite concentrations across cortical regions in healthy adults. Brain Res (2010) 0.91
Relationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses. Schizophr Res (2011) 0.90
Age-related changes in brain energetics and phospholipid metabolism. NMR Biomed (2010) 0.90
Clozapine interaction with phosphatidyl inositol 3-kinase (PI3K)/insulin-signaling pathway in Caenorhabditis elegans. Neuropsychopharmacology (2009) 0.90
Behavioral effects of short-term administration of lithium and valproic acid in rats. Brain Res (2006) 0.90
Creatine kinase and ATP synthase reaction rates in human frontal lobe measured by ³¹P magnetization transfer spectroscopy at 4T. Magn Reson Imaging (2012) 0.89
Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy (2004) 0.89
Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology (2009) 0.87
Cerebellar blood volume in bipolar patients correlates with medication. Biol Psychiatry (2002) 0.87
Oral choline increases choline metabolites in human brain. Psychiatry Res (2004) 0.86
Medication adherence and attitudes in patients with bipolar disorder and current versus past substance use disorder. Psychiatry Res (2011) 0.86
Perceptual training strongly improves visual motion perception in schizophrenia. Brain Cogn (2011) 0.86
Electroconvulsive seizures stimulate glial proliferation and reduce expression of Sprouty2 within the prefrontal cortex of rats. Biol Psychiatry (2007) 0.86
Brain-to-serum lithium ratio and age: an in vivo magnetic resonance spectroscopy study. Am J Psychiatry (2002) 0.86
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats. Biol Psychiatry (2005) 0.85
Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study. Ann Acad Med Singapore (2009) 0.85
Antidepressant-like effects of cytidine in the forced swim test in rats. Biol Psychiatry (2002) 0.84
Auditory hallucinations in a cross-diagnostic sample of psychotic disorder patients: a descriptive, cross-sectional study. Compr Psychiatry (2011) 0.84
Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol (2012) 0.83
Neurophysiologic effect of GWAS derived schizophrenia and bipolar risk variants. Am J Med Genet B Neuropsychiatr Genet (2013) 0.83
Probing myelin and axon abnormalities separately in psychiatric disorders using MRI techniques. Front Integr Neurosci (2013) 0.83
Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients. Exp Clin Psychopharmacol (2008) 0.83
Expression of noradrenergic alpha1, serotoninergic 5HT2a and dopaminergic D2 receptors on neurons activated by typical and atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.83
Behavioral effects of clozapine: involvement of trace amine pathways in C. elegans and M. musculus. Brain Res (2011) 0.82
How blind is double-blind? A study of fish oil versus placebo. Prostaglandins Leukot Essent Fatty Acids (2002) 0.82
S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects. Biol Psychiatry (2003) 0.82
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.82
Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disord (2013) 0.81
Transient receptor potential melastatin (TRPM) channels mediate clozapine-induced phenotypes in Caenorhabditis elegans. J Neurogenet (2014) 0.81
Variations in the dopamine beta-hydroxylase gene are not associated with the autonomic disorders, pure autonomic failure, or multiple system atrophy. Am J Med Genet A (2003) 0.81